Učitavanje...

Targeting the Plasmodium vivax equilibrative nucleoside transporter 1 (PvENT1) for antimalarial drug development

Infection with Plasmodium falciparum and vivax cause most cases of malaria. Emerging resistance to current antimalarial medications makes new drug development imperative. Ideally a new antimalarial drug should treat both falciparum and vivax malaria. Because malaria parasites are purine auxotrophic,...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Int J Parasitol Drugs Drug Resist
Glavni autori: Deniskin, Roman, Frame, I.J., Sosa, Yvett, Akabas, Myles H.
Format: Artigo
Jezik:Inglês
Izdano: Elsevier 2015
Teme:
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4706624/
https://ncbi.nlm.nih.gov/pubmed/26862473
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ijpddr.2015.11.003
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!